Editas Medicine Inc (EDIT)
5.36
+0.14
(+2.78%)
USD |
NASDAQ |
May 01, 14:08
Editas Medicine Enterprise Value: 103.55M for April 30, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 30, 2024 | 103.55M |
April 29, 2024 | 116.23M |
April 26, 2024 | 112.14M |
April 25, 2024 | 103.96M |
April 24, 2024 | 114.59M |
April 23, 2024 | 123.59M |
April 22, 2024 | 135.05M |
April 19, 2024 | 126.05M |
April 18, 2024 | 130.96M |
April 17, 2024 | 135.86M |
April 16, 2024 | 155.50M |
April 15, 2024 | 174.32M |
April 12, 2024 | 184.95M |
April 11, 2024 | 215.22M |
April 10, 2024 | 219.32M |
April 09, 2024 | 250.40M |
April 08, 2024 | 226.68M |
April 05, 2024 | 226.68M |
April 04, 2024 | 234.04M |
April 03, 2024 | 238.13M |
April 02, 2024 | 238.95M |
April 01, 2024 | 272.49M |
March 28, 2024 | 283.95M |
March 27, 2024 | 285.58M |
March 26, 2024 | 267.59M |
Date | Value |
---|---|
March 25, 2024 | 279.04M |
March 22, 2024 | 288.04M |
March 21, 2024 | 317.49M |
March 20, 2024 | 324.86M |
March 19, 2024 | 310.95M |
March 18, 2024 | 308.49M |
March 15, 2024 | 342.04M |
March 14, 2024 | 343.67M |
March 13, 2024 | 379.67M |
March 12, 2024 | 381.31M |
March 11, 2024 | 413.21M |
March 08, 2024 | 426.30M |
March 07, 2024 | 400.94M |
March 06, 2024 | 419.76M |
March 05, 2024 | 424.67M |
March 04, 2024 | 488.48M |
March 01, 2024 | 538.39M |
February 29, 2024 | 499.94M |
February 28, 2024 | 582.57M |
February 27, 2024 | 401.76M |
February 26, 2024 | 336.31M |
February 23, 2024 | 315.86M |
February 22, 2024 | 325.30M |
February 21, 2024 | 331.85M |
February 20, 2024 | 326.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
103.55M
Minimum
Apr 30 2024
5.265B
Maximum
Jan 08 2021
1.086B
Average
778.80M
Median
Oct 02 2019
Enterprise Value Benchmarks
Vertex Pharmaceuticals Inc | 90.24B |
Moderna Inc | 33.62B |
Amicus Therapeutics Inc | 3.051B |
Geron Corp | 1.892B |
Regeneron Pharmaceuticals Inc | 88.89B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -18.87M |
Revenue (Quarterly) | 60.05M |
Total Expenses (Quarterly) | 84.01M |
EPS Diluted (Quarterly) | -0.23 |
Profit Margin (Quarterly) | -31.43% |
Earnings Yield | -38.25% |
Normalized Earnings Yield | -38.25 |